Research output per year
Research output per year
Personal profile
Biography
Dr Reyhaneh is a Lecturer at Jeffrey Cheah School of Medicine and Health Sciences. She obtained her PhD degree in Molecular Medicine from University of Malaya (UM) in 2019. Her PhD project was awarded for the Postgraduate Research Grant from University of Malaya focusing on molecular and cellular mechanism of action of anti-breast cancer activity of novel Schiff-based compounds as the promising anticancer agents in breast cancer treatment.
Dr Reyhaneh is a scientist with keen interests in anti-cancer drug discovery and development. Her certain unique set of skills, knowledge and experiences has led to several publications in internationally reputed high impact journals. Last but not the least, Dr Reyhaneh's dream is to make a difference in fighting against breast cancer and she is currently working on natural product in breast cancer therapy.
Research interests
Molecular oncology, Cancer drug discovery, Cancer therapy
Monash teaching commitment
NUT1021 - Fundamentals of Human Nutrition
MED 2100/2200 - Student Project Cases (SPC)
MED 5101 - Scholarly Intensive Placement (SIP)
MED 2100 - Interprofessional Learning (IPL)
BRM5011-Foundations for Medical Biotechnology and its Applications
Expertise related to UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):
Education/Academic qualification
Molecular Medicine, Doctor of Philosophy, In Vitro Anti-Breast Cancer Study and In Vivo Acute Toxicity Evaluation of Novel Indole Schiff-Based Compounds, Tetradentate Β-Diiminato Ligand And Its ManganeseIII Complex, Universiti Malaya (University of Malaya)
Sept 2015 → Aug 2019
Award Date: 22 Aug 2019
Biotechnology, Master of Science, Polymorphism Study of The Mitochondrial DNA Cytochrome B Gene in The Malay Population., Universiti Teknologi Malaysia (University of Technology Malaysia)
Jan 2011 → Mar 2013
Award Date: 13 Mar 2013
Cellular & Molecular Biology- Genetics, Bachelor of Science, Shahrekord University
2005 → 2009
Award Date: 18 Aug 2009
Research area keywords
- Cancer therapy
- Apoptosis
- Biomedical science
- Breast cancer
- Singnaling pathway
- Cytotoxicity
- Anti-cancer drug screening
- Drug Discovery
- TNBC
- Cell Culture
- Natural products
- Shaghayegh
- Rihanna
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Long non-coding RNAs and drug resistance in breast cancer patients: a scoping review
Lee, J. S. Y. (Leading Author), Palanisamy, U. D., Magalingam, K. B., Farghadani, R. & Radhakrishnan, A. K. C., 2025, In: Cancer Plus. 7, 3, p. 73–88 16 p.Research output: Contribution to journal › Review Article › Research › peer-review
Open Access -
Reprogramming the breast tumor immune microenvironment: cold-to-hot transition for enhanced immunotherapy
Imani, S., Farghadani, R., Roozitalab, G., Maghsoudloo, M., Emadi, M., Moradi, A., Abedi, B. & Jabbarzadeh Kaboli, P., 25 Apr 2025, In: Journal of Experimental and Clinical Cancer Research. 44, 1, 51 p., 131.Research output: Contribution to journal › Review Article › Research › peer-review
Open Access22 Citations (Scopus) -
c-MET and the immunological landscape of cancer: novel therapeutic strategies for enhanced anti-tumor immunity
Jabbarzadeh Kaboli, P., Roozitalab, G., Farghadani, R., Eskandarian, Z. & Zerrouqi, A., 27 Nov 2024, In: Frontiers in Immunology. 15, 28 p., 1498391.Research output: Contribution to journal › Review Article › Research › peer-review
Open Access10 Citations (Scopus) -
Comprehensive assessment of TECENTRIQ® and OPDIVO®: analyzing immunotherapy indications withdrawn in triple-negative breast cancer and hepatocellular carcinoma
Roozitalab, G., Abedi, B., Imani, S., Farghadani, R. & Jabbarzadeh Kaboli, P., Sept 2024, In: Cancer and Metastasis Reviews. 43, 3, p. 889–918 30 p.Research output: Contribution to journal › Review Article › Research › peer-review
6 Citations (Scopus) -
Novel indole Schiff base β-diiminato compound as an anti-cancer agent against triple-negative breast cancer: In vitro anticancer activity evaluation and in vivo acute toxicity study
Farghadani, R., Lim, H. Y., Abdulla, M. A. & Rajarajeswaran, J., Nov 2024, In: Bioorganic Chemistry. 152, 12 p., 107730.Research output: Contribution to journal › Article › Research › peer-review
Open Access6 Citations (Scopus)
-
Phytochemistry Reviews (Journal)
Farghadani, R. (Peer reviewer)
2024Activity: Publication peer-review and editorial work types › Peer review responsibility
-
12th International Scientific Research and Innovation Congress
Farghadani, R. (Speaker)
3 Mar 2024 → 4 Mar 2024Activity: Participating in or organising an event types › Contribution to conference
-
Non-coding RNA World 2024: Exploring Mechanisms, Designing Medicines
Lee, J. S. Y. (Speaker), Bai, K. (Speaker), Palanisamy, U. D. (Speaker), Farghadani, R. (Speaker) & Radhakrishnan, A. (Speaker)
7 Oct 2024 → 9 Oct 2024Activity: Participating in or organising an event types › Contribution to conference
-
National Cancer Congress Malaysia
Lee, J. S. Y. (Speaker), Bai, K. (Speaker), Palanisamy, U. (Speaker), Farghadani, R. (Organiser) & Radhakrishnan, A. (Speaker)
21 Jun 2024 → 23 Jun 2024Activity: Participating in or organising an event types › Contribution to conference
-
Unraveling the Enigma of Cachexia in Breast Cancer: A Comprehensive Narrative Review
Radhakrishnan, A. (Supervisor), Ramdas, P. (Supervisor) & Farghadani, R. (Supervisor)
3 Mar 2024 → 12 Apr 2024Activity: Other Teaching Engagements and non-HDR Supervisions › Non-HDR Supervisions